

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 2, 2006

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-12957

22-2372868

(State or other jurisdiction of incorporation) (Commission File No.) (IRS Identification No.)

685 Route 202/206, Bridgewater, New Jersey

08807

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (908) 541-8600

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 2, 2006, Enzon Pharmaceuticals, Inc. ("Enzon") issued a press release reporting certain financial and other information for the quarter ended September 30, 2006. A copy of Enzon's press release dated November 2, 2006, is attached as Exhibit 99.1 to this Current Report and is incorporated by reference into this Item 2.02.

The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liability of that Section, nor shall such information be deemed to be

incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as otherwise stated in that filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

EXHIBIT NO. -----	DESCRIPTION -----
99.1	Press Release of Enzon Pharmaceuticals, Inc. dated November 2, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 2, 2006

By: /s/ Craig A. Tooman

Craig A. Tooman

Executive Vice President, Finance and Chief
Financial Officer

Contact: Craig Tooman
EVP, Finance and Chief
Financial Officer
908-541-8777

ENZON REPORTS THIRD QUARTER 2006 RESULTS
-- TURNAROUND MAKES VISIBLE PROGRESS --

BRIDGEWATER, NJ - November 2, 2006 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the third quarter of 2006. For the three months ended September 30, 2006, Enzon reported net income of \$2.2 million or \$0.05 per diluted share, as compared to a net loss of \$5.8 million or \$(0.13) per diluted share.

"We are pleased to report another solid quarter, but more importantly, we are enthusiastic about the Company's momentum toward rebuilding the pipeline, maximizing our current brands and recruiting top talent to lead the organization in achieving the next level of success," said Jeffrey H. Buchalter, chairman and chief executive officer of Enzon. "Over the past year, we have been able to leverage and modernize the Company's core asset, PEGylation technology, by integrating it with novel oncology candidates, setting the stage for a new, innovative pipeline from the Company."

COMPANY UPDATES:

- The Company's rhMBL program expands with the approval of an additional Investigational New Drug (IND) application for use in the prevention and treatment of severe infections in patients with low levels of MBL undergoing liver transplant treatment.
- The Company's Santaris Pharma A/S collaboration, which was established in July of this year, is on track and the Company anticipates filing an IND for the HIF-1 alpha antagonist by the end of 2006.
- The Company expects to have data presented at upcoming medical conferences on three of its research and development projects. These include: rhMBL, recombinant human Manose Binding Lectin for immuno-suppressed patients, Oncaspar(R), a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase, and PEG-SN38, a PEGylated form of the active moiety of CPT-11 or Camptosar(R).

-more-

-2-

FINANCIAL RESULTS

REVENUES

The following table reflects the revenues generated by product and segment for each of the three-month periods ended September 30, 2006 and 2005.

Table with 3 columns: Three Months Ended, September 30, 2006, September 30, 2005, and % Change. Includes a note '(in thousands)'.

Products			
Oncaspar	\$7,418	\$5,789	28%
Depocyt	2,000	2,334	(14%)
Abelcet	8,986	11,113	(19%)
Adagen	6,891	5,940	16%
	-----	-----	-----
TOTAL PRODUCTS	25,295	25,176	n.m.
ROYALTIES	18,705	15,478	21%
CONTRACT MANUFACTURING	1,856	3,393	(45%)
	-----	-----	-----
TOTAL REVENUES	\$ 45,856	\$ 44,047	4%
	=====	=====	=====

PRODUCTS SEGMENT

Sales from the products segment, comprised of Oncaspar(R), Depocyt(R), Abelcet(R), and Adagen(R), increased slightly to \$25.3 million for the three months ended September 30, 2006, from \$25.2 million for the three months ended September 30, 2005.

Sales of Oncaspar grew to \$7.4 million or 28 percent for the three months ended September 30, 2006, as compared to \$5.8 million for the three months ended September 30, 2005. The growth of Oncaspar is mainly attributable to its adoption in certain protocols by hospitals and cooperative groups. On July 25, 2006, the Company announced the approval of Oncaspar for the first line treatment of acute lymphoblastic leukemia (ALL).

Sales of Depocyt, a sustained-release formulation of the chemotherapeutic agent cytarabine arabinoside or ara-C used for the treatment of lymphomatous meningitis, decreased to \$2.0 million or 14 percent for the three months ended September 30, 2006, as compared to \$2.3 million for the three months ended September 30, 2005.

Sales of Abelcet in the U.S. and Canada, a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections, for the three months ended September 30, 2006 were \$9.0 million, down 19 percent as compared to \$11.1 million for the three months ended September 30, 2005. The decrease was primarily the result of expected competition from current and newly launched therapeutics in the anti-fungal market.

-more-

-3-

Sales of Adagen, an enzyme replacement therapy used to treat adenosine deaminase (ADA) deficiency in patients with severe combined immuno-deficiency disease, increased 16 percent to \$6.9 million for the three months ended September 30, 2006, as compared to \$6.0 million for the three months ended September 30, 2005. This market has a very small number of patients so quarter-to-quarter variability is not uncommon.

ROYALTIES SEGMENT

Revenues from the Company's Royalties segment for the three months ended September 30, 2006 were \$18.7 million, as compared to \$15.4 million for the three months ended September 30, 2005, an increase of 21 percent. Royalties on PEG-INTRON, marketed by Schering-Plough, continue to comprise the majority of our royalty revenue. Schering-Plough has recently indicated that they anticipate a decline in PEG-INTRON sales in Japan as new patient enrollment moderates and competition increases.

CONTRACT MANUFACTURING SEGMENT

The Company's revenues from its Contract Manufacturing segment were \$1.9 million for the three months ended September 30, 2006, as compared to \$3.4 million in the corresponding period of the prior year. This includes contract manufacturing revenues related to services the Company provides for customers who require injectable products, such as Abelcet for markets outside of Canada and the U.S. During the quarter, the revenue reconciliation for two contract manufacturing products resulted in a reduction of revenue of \$1.2 million. The timing of

production of another product Enzon manufactures also resulted in lower revenues.

RESEARCH AND DEVELOPMENT

The Company's research and development expenses were \$10.6 million for the three months ended September 30, 2006, as compared to \$5.3 million for the three months ended September 30, 2005. The increase was attributable to initiation of programs in 2006. Research and development expenses last year was impacted by the restructuring that occurred in the second quarter of 2005. Enzon is committed to investing in research and development to build a leading oncology business through the continued development of its current portfolio, reinforcing its position as a scientific leader in PEGylation through its Customized Linker Technology(TM) platforms and strategic in-licensing of innovative cancer programs, as demonstrated by the Company's strategic collaboration with Santaris reported last quarter.

SELLING, GENERAL AND ADMINISTRATIVE

Selling, general and administrative expenses increased to \$14.3 million for the three months ended September 30, 2006, as compared to \$11.7 million for the three months ended September 30, 2005. The increase is mainly attributable to the costs associated with the Company's debt refinancing completed this quarter. The Company will continue to invest in selling, marketing, and other initiatives to further its objective of delivering long-term value, including improving its top-line performance by investing in its commercial operations.

-more-

-4-

AMORTIZATION OF ACQUIRED INTANGIBLE ASSETS

Amortization expense decreased by \$3.1 million to \$184 thousand for the three months ended September 30, 2006, as compared to \$3.3 million for the three months ended September 30, 2005. The decrease is a result of the Abelcet intangible write-down which occurred in December 2005.

ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT

In August 2006, we paid \$8.0 million for worldwide rights to develop and commercialize certain RNA antagonists. During the third quarter of last year, the Company paid \$10.0 million for the rights to the clinical development of recombinant human Mannose-Binding Lectin.

OTHER INCOME (EXPENSE)

Net other income (expense) is comprised of investment income, interest expense, and other non-operating expenses. The Company reported other income of approximately \$1.8 million for the three months ended September 30, 2006, as compared to other expense of nearly \$6.3 million in the same period in the prior year. In July 2006, the Company completed its debt refinancing by repurchasing \$137.6 million of the 4.5% notes due in 2008, which resulted in a gain of \$4.8 million. This gain was offset by the write-off of \$1.2 million in deferred offering costs associated with the 2008 convertible notes repurchased. In 2005, the Company reported a loss of \$3.5 million related to the maturing of a financial instrument the Company formed to reduce its investment risk associated with 1.5 million shares of NPS Pharmaceuticals, Inc. (NPS) common stock received in June 2003.

INCOME TAXES

For the three months ended September 30, 2006, the Company recognized a nominal amount of state and Canadian tax liabilities. For 2006, the estimated effective annual U.S. income tax rate is nominal due to the Company's projected taxable income and availability of net operating loss carryforwards.

CASH AND INVESTMENTS

Total cash reserves, which include cash, cash equivalents, short-term investments and marketable securities, were \$240.4 million as of September 30, 2006, as compared to \$226.6 million as of December 31, 2005. Positive operating cash flows for the nine-month period ended September 30, 2006 and cash proceeds from the sale of Nektar common stock the Company owned contributed to the increase in cash. Offsetting these cash inflows was the January payment to Sanofi-Aventis of \$35.0 million relating to a reduction of the Oncaspar royalty

rate.

- more -

-5-

RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED NET INCOME (LOSS)

For the three months ended September 30, 2006, Enzon reported an adjusted net loss of \$1.3 million or \$(0.03) per diluted share, as compared to an adjusted net loss of \$2.3 million or \$(0.05) per diluted share for the three months ended September 30, 2005.

The following table reconciles the Company's net income (loss) and net income (loss) per diluted share as determined in accordance with U.S. generally accepted accounting principles (GAAP) to its adjusted net loss and adjusted net loss per diluted share for the three months ended September 30, 2006 and 2005:

	Three Months Ended			
	(in thousands, except per-share amounts)			
	September 30, 2006		September 30, 2005	
	Net income (loss)	Net income (loss) per diluted share	Net Loss	Net loss per diluted share
GAAP net income (loss)	\$ 2,238	\$ 0.05	\$ (5,766)	\$ (0.13)
Net adjustments to GAAP:				
- Net realized gain related to the repurchase of debt (1)	(3,569)	(0.08)		
- Net realized loss related to the sale of NPS common stock (2)	-	-	3,460	0.08
Adjusted net loss (3)	\$ (1,331)	\$ (0.03)	\$ (2,306)	\$ (0.05)

- (1) The Company's adjusted financial results for the third quarter of 2006 exclude a gain related to the repurchase of the 4.5% Notes at a price of \$965 (plus accrued interest) for each \$1,000 principal amount of notes tendered, offset by a write-off of related debt offering costs.
- (2) The Company's adjusted financial results for the September quarter of 2005 exclude a net-of-tax realized loss of \$3.5 million related to the maturing of a financial instrument the Company formed to reduce its investment risk associated with 1.5 million shares of NPS Pharmaceuticals, Inc. (NPS) common stock received in June 2003. The Company received the common stock under a merger termination agreement with NPS.
- (3) Adjusted net loss and adjusted net loss per diluted share, as the Company defines them, may differ from similarly named measures used by other entities, and consequently, could be misleading unless all entities calculated and defined such items in the same manner. The Company believes that investors' understanding of its performance is enhanced by disclosing adjusted net income (loss) and adjusted net income (loss) per diluted share reflecting adjustments for certain items that the Company deems to be non-recurring.

-more-

CONFERENCE CALL AND WEBCAST

Enzon will be hosting a conference call November 2, 2006 at 9:00am E.S.T. All interested parties may access the call by using the following information:

Domestic Dial-In Number: (866) 585-6398
International Dial-In Number: (416) 849-9626
Access Code: Enzon

Enzon's conference call will also be webcast in a "listen only" mode via the Internet at <http://www.vcall.com>. Additionally, for those parties unable to listen at the time of Enzon's conference call, a telephone rebroadcast will be available following the call from November 2, 2006, at approximately 12:00 p.m. E.S.T. This rebroadcast will end on November 9, 2006, at approximately 11:59 p.m. E.S.T. The rebroadcast may be accessed using the following information:

Domestic Dial-In Number: (866) 245-6755
International Dial-In Number: (416) 915-1035
Access Code: 80421

ABOUT ENZON

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology™ PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. The Company also engages in contract manufacturing opportunities with third parties to improve its efficiency. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our transition report on Form 10-K for the six-month period ended December 31, 2005 and our quarterly reports on Form 10-Q. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.

(Financial information to follow)

Enzon Pharmaceuticals, Inc. and Subsidiaries
Consolidated Statements of Operations
THREE MONTHS ended September 30, 2006 and 2005
(In thousands, except per share data)
(Unaudited)

	September 30, 2006	September 30, 2005
Revenues:		
Product sales, net	\$ 25,295	\$ 25,176
Royalties	18,705	15,478
Contract manufacturing	1,856	3,393
Total revenues	45,856	44,047
Costs and expenses:		
Cost of product sales and contract manufacturing	12,141	11,964
Research and development	10,599	5,319
Selling, general and administrative	14,299	11,697
Amortization of acquired intangible assets	184	3,348
Acquired in-process research and development	8,000	10,000
Total costs and expenses	45,223	42,328
Operating income	633	1,719
Other income (expense):		
Investment income, net	2,831	1,632
Interest expense	(5,912)	(4,946)
Other, net	4,813	(3,059)
Income (loss) before income tax provision	2,365	(4,654)
Income tax provision	127	1,112
Net income (loss)	\$ 2,238	\$ (5,766)
Earnings (loss) per common share - basic	\$ 0.05	\$ (0.13)
Earnings (loss) per common share - diluted	\$ 0.05	\$ (0.13)
Weighted average shares - basic	43,590	43,486
Weighted average shares - diluted	43,590	43,486

-more-

-8-

Enzon Pharmaceuticals, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
September 30, 2006 and December 31, 2005
(In thousands)
(Unaudited)

	September 30, 2006	December 31 2005
Assets		
Current assets:		
Cash and short-term investments	\$ 169,985	\$ 164,518
Accounts receivable, net	11,798	14,087
Inventories	18,381	16,014
Other current assets	6,211	12,596
Total current assets	206,375	207,215
Property and equipment, net	37,576	34,978
Other assets:		
Marketable securities	70,458	62,059

Amortizable intangible assets, net	63,093	34,154
Other long-term assets	6,873	2,939
	-----	-----
	140,424	99,152
	-----	-----
Total assets	\$ 384,375	\$ 341,345
	=====	=====
Liabilities and Stockholders' Deficit		
Current and other liabilities	\$31,087	\$31,315
Notes payable	397,642	394,000
Stockholders' deficit	(44,354)	(83,970)
	-----	-----
Total liabilities and stockholders' deficit	\$ 384,375	\$ 341,345
	=====	=====
Common shares outstanding	43,877	43,787
	=====	=====

#